392 related articles for article (PubMed ID: 19185026)
1. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
2. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
3. Dynamic expression of Hsp27 in the presence of mutant ataxin-3.
Chang WH; Cemal CK; Hsu YH; Kuo CL; Nukina N; Chang MH; Hu HT; Li C; Hsieh M
Biochem Biophys Res Commun; 2005 Oct; 336(1):258-67. PubMed ID: 16126176
[TBL] [Abstract][Full Text] [Related]
4. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease.
Chang WH; Tien CL; Chen TJ; Nukina N; Hsieh M
Neurosci Lett; 2009 Apr; 454(2):152-6. PubMed ID: 19429074
[TBL] [Abstract][Full Text] [Related]
5. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
6. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.
Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK
PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985
[TBL] [Abstract][Full Text] [Related]
7. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
8. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
9. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
10. Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
Hsieh M; Hsieh BY; Ma CY; Li YT; Liu CS; Lo CM
J Neurosci Res; 2019 Oct; 97(10):1278-1297. PubMed ID: 31157458
[TBL] [Abstract][Full Text] [Related]
11. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
12. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
13. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
15. The polyglutamine-expanded protein ataxin-3 decreases bcl-2 mRNA stability.
Tien CL; Wen FC; Hsieh M
Biochem Biophys Res Commun; 2008 Jan; 365(2):232-8. PubMed ID: 17983597
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of carbonic anhydrase-related protein XI in neuronal cells expressing mutant ataxin-3.
Hsieh M; Chang WH; Hsu CF; Nishimori I; Kuo CL; Minakuchi T
Cerebellum; 2013 Jun; 12(3):338-49. PubMed ID: 23184527
[TBL] [Abstract][Full Text] [Related]
17. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
18. Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway.
Wu YL; Chang JC; Lin WY; Li CC; Hsieh M; Chen HW; Wang TS; Wu WT; Liu CS; Liu KL
Free Radic Biol Med; 2018 Feb; 115():309-317. PubMed ID: 29247688
[TBL] [Abstract][Full Text] [Related]
19. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3.
Araujo J; Breuer P; Dieringer S; Krauss S; Dorn S; Zimmermann K; Pfeifer A; Klockgether T; Wuellner U; Evert BO
Hum Mol Genet; 2011 Aug; 20(15):2928-41. PubMed ID: 21536589
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
